Company intelligence / Profile preview
Hunazine Biotech
- Ownership
- Private
- Employees
- ~5
- Development stage
- Phase 2
Overview
Hunazine Biotech S.L. is a Spanish biotech company focused exclusively on developing novel treatments for cholera and severe diarrheal diseases. Its lead asset, VR‑AD‑1005, a small molecule licensed from Vanessa Biotech, has advanced to Phase 2 clinical trials targeting symptomatic relief in cholera patients by reducing stool volume without affecting gut motility or causing constipation. The company claims this approach addresses the challenge of convective washout that limits efficacy of current antidiarrheals in acute watery diarrhea.
- Therapeutic areas
- GastroenterologyRare DiseasesInfectious Diseases
- Modalities
- Small molecule drug
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Hunazine Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hunazine Biotech.